Aton Pharma Launches Extended Program for Preservative-Free Timoptic® in Ocudose®
August 27, 2009
Aton Pharma, Inc. has announced that it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC® in OCUDOSE®, the only preservative-free medication for glaucoma available in the United States. Aton acquired the marketing rights to the Timoptic product line from Merck & Co., Inc. in February.
Aton will support TIMOPTIC in OCUDOSE with ophthalmic journal advertising, a couponing program, direct mail promotion and a patient information website. The sales force will re-introduce TIMOPTIC in OCUDOSE to eye care professionals as well.
Aton conducted a survey of ophthalmologists and found that 97% of those surveyed felt that preservative-free glaucoma medications could enhance the comfort of glaucoma patients. Nine out of ten surveyed that there are not enough preservative-free glaucoma medications available while almost one-half did not know that any preservative-free glaucoma beta-blocker medications existed. The presence of a preservative-free glaucoma medication may have an impact in the treatment of patients with glaucoma and dry eyes or lid margin disease.
Read the press release.
Jump down to form below to submit your own comments